Humacyte reports Q3 EPS (11c), consensus (15c)

Reports Q3 revenue $753,000, consensus $922,830. “During the third quarter of 2025 we continued to execute on our U.S. commercial launch of Symvess with sales increasing substantially, totaling $703,000 for third quarter compared to $100,000 in second quarter,” said Laura Niklason, CEO. “This significant ramp-up is due to an increased number of individual hospital and healthcare system Value Analysis Committee approvals, our recent inclusion in the U.S. Defense Logistics Agency’s Electronic Catalog, and the tireless work of our commercial and medical teams in educating the vascular surgery community about the benefits of Symvess. The launch of Symvess in the vascular trauma indication is just the first of the many planned products emerging from our proprietary bioengineering platform, and the advancement of our broader pipeline was supported by multiple events during the quarter. The acellular tissue engineered vessel is moving closer to our planned supplemental Biologics License Application filing in dialysis access. This planned dialysis indication is supported by positive two-year results from the V007 Phase 3 trial presented last weekend at Kidney Week 2025, which is the world’s largest nephrology meeting. For coronary artery bypass grafting, we published positive results of a preclinical study evaluating our coronary tissue engineered vessel in non-human primates. These results support our plans to advance the CTEV into a human study in CABG in 2026. If successful, the CTEV would be the first novel conduit tested in CABG in the US in decades. Lastly, we expanded our intellectual property estate with the grant of a new U.S. patent for our bioengineered esophagus, complementing our existing intellectual property in urinary conduits and tracheas, all of which can be produced using our proprietary regenerative tissue engineering platform.”